Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.
Frontiers in Psychiatry 2024 Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca et al. 31 citations
Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many...